Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer

Inclusion Criteria: * Histologically documented adenocarcinoma of the stomach or gastroesophageal junction. * Invasion to adjacent organ (T4) proven by endoscopic ultrasonography (EUS) or presence of paraaortic lymph node metastasis by CT and PET(short-axis diameter \> 1 cm showing hot uptake in PET scan). * Age 18-70 years old * ECOG performance status 0-2 * Adequate hepatic function(serum bilirubin \<1.5mg/dl, AST (SGOT) and ALT (SGPT) \< 2.5 x UNL, alkaline phosphatase \< 5 x UNL) * Adequate renal function(serum creatinine \<1.5mg/dl) * Adequate bone marrow function (WBC ≥4000 cell/㎕ with ANC ≥1500 cell/㎕, platelet count ≥100,000 cell/㎕) * HER2 negative (HER2 immunohistochemistry 0 or 1+, immunohistochemistry 2+ but FISH negative) * Informed consent Exclusion Criteria: * Other histologic type than adenocarcinoma * Metastasis in other sites than paraaortic lymph nodes, like in liver or peritoneum. * Presence or history of other cancers * History of prior chemotherapy, antiangiogenic agents, or radiation. * Patients with definite ascites in abdomen CT scan * Presence of not adequately controlled CNS metastasis * Bowel obstruction * Evidence of gastrointestinal bleeding * Other serious illness or medical conditions including hypertension uncontrolled by medication. * Pregnant or lactating women